Lycopene
drugOn this page
Also known as (all-e)-lycopene(all-trans)-lycopeneAec lycopeneAterononBlakeslea trisporaCi 75125E-160D(III)E160dFEMA NO. 4110INS NO.160D(III)INS-160D(III)Lycopene from blakeslea trisporaLycopene preparationLycoredMexoryl saqNSC-407322RedivivoSolanorubinTomat-o-red
Summary
Lycopene (CHEMBL501174) is a phase-3 clinical-stage small-molecule antioxidant; indicated across 9 conditions including coronary artery disorder and atherosclerosis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 9 conditions
- Clinical trials: 35
- Chemistry: 536.9 Da · C40H56
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL501174 |
| Name | Lycopene |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 446925 |
| ChEBI | CHEBI:15948 |
| Molecular formula | C40H56 |
| Molecular weight | 536.9 |
| InChIKey | OAIJSZIZWZSQBC-GYZMGTAESA-N |
SMILES: CC(=CCC/C(=C/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=C(/CCC=C(C)C)\C)\C)\C)/C)/C)/C)C
IUPAC name: (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene
ChEBI definition: An acyclic carotene commonly obtained from tomatoes and other red fruits.
Pharmacological roles (ChEBI): antioxidant.
Other ChEBI roles (chemical / environmental): plant metabolite.
Also known as: (all-e)-lycopene, (all-trans)-lycopene, Aec lycopene, Ateronon, Blakeslea trispora, Ci 75125, E-160D(III), E160d, FEMA NO. 4110, INS NO.160D(III), INS-160D(III), Lycopene
Patent coverage: 20,915 distinct patent families (54,416 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Progesterone receptor, Androgen receptor, Nuclear receptor subfamily 1 group I member 2.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| NR1I2 | 5.28 | AC50 | 5300 | nM | CHEMBL_ACT_25188377 |
| PGR | 5.21 | AC50 | 6200 | nM | CHEMBL_ACT_25222340 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| coronary artery disorder | 3 | MONDO:0005010 | EFO:0001645 |
| atherosclerosis | 3 | MONDO:0005311 | EFO:0003914 |
| benign prostatic hyperplasia | 2 | MONDO:0010811 | EFO:0000284 |
| prostate adenocarcinoma | 2 | MONDO:0005082 | EFO:0000673 |
| lichen planus | 2 | MONDO:0006572 | EFO:1000726 |
| periodontitis | 1 | MONDO:0005076 | EFO:0000649 |
| prostate intraepithelial neoplasia | 1 | MONDO:0005193 | EFO:0002621 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 35.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 12 |
| Not specified | 11 |
| PHASE1 | 6 |
| PHASE3 | 3 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02587117 | PHASE4 | COMPLETED | A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus |
| NCT00939237 | PHASE3 | COMPLETED | Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease |
| NCT01105338 | PHASE2/PHASE3 | COMPLETED | Lycopene or Green Tea for Men at Risk of Prostate Cancer |
| NCT01221558 | PHASE3 | COMPLETED | Effects of Lycopene on Oxidative Stress and Markers of Endothelial Function Healthy Men |
| NCT01287182 | PHASE3 | COMPLETED | Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis |
| NCT00068731 | PHASE2 | COMPLETED | Lycopene in Treating Patients With Metastatic Prostate Cancer |
| NCT00154843 | PHASE2 | COMPLETED | A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation |
| NCT00172367 | PHASE2 | WITHDRAWN | Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma |
| NCT00450749 | PHASE2 | COMPLETED | Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer |
| NCT00656214 | PHASE2 | COMPLETED | Treatmant of Oral Lichen Planus With Lycopene |
| NCT00744549 | PHASE2 | COMPLETED | Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance |
| NCT00844792 | PHASE2 | COMPLETED | Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer |
| NCT00905931 | PHASE2 | UNKNOWN | Lycopene Following Aneurysmal Subarachnoid Haemorrhage |
| NCT01443026 | PHASE2 | COMPLETED | The Effects of Lycopene on High Risk Prostatic Tissue |
| NCT01882985 | PHASE2 | COMPLETED | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients |
| NCT03167268 | PHASE2 | UNKNOWN | Panitumumab Skin Toxicity Prevention Trial |
| NCT03203746 | PHASE1/PHASE2 | COMPLETED | Gingival Crevicular Fluid Levels of Protein Carbonyl Following the Use of Lycopene in Chronic Periodontitis |
| NCT03964935 | PHASE2 | UNKNOWN | Lycopene vs Minocycline Hydrochloride as Adjunctive to Periodontal Treatment |
| NCT00006078 | PHASE1 | COMPLETED | Lycopene In Preventing of Prostate Cancer |
| NCT00093561 | PHASE1 | COMPLETED | Lycopene in Preventing Prostate Cancer in Healthy Participants |
| NCT00178113 | PHASE1 | COMPLETED | A Pilot Study of Lycopene Supplementation in Prostatic Intraepithelial Neoplasia |
| NCT00416325 | PHASE1 | COMPLETED | Lycopene in Preventing Prostate Cancer in Patients Who Are at High Risk of Developing Prostate Cancer |
| NCT00450957 | PHASE1 | COMPLETED | Lycopene in Healthy Male Participants |
| NCT01949519 | PHASE1 | COMPLETED | Docetaxel and Lycopene in Metastatic Prostate Cancer |
| NCT00042731 | Not specified | COMPLETED | Isoflavones & Lycopene in Localized Prostate Ca:Prior to Radical Prostatectomy |
| NCT00322114 | Not specified | UNKNOWN | Lycopene in Preventing Prostate Cancer in Healthy Participants |
| NCT00402285 | Not specified | COMPLETED | Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer |
| NCT00416390 | Not specified | COMPLETED | Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia |
| NCT01100385 | Not specified | COMPLETED | TomVasc - Vascular Effects of Tomato Extract |
| NCT01102504 | Not specified | WITHDRAWN | Supplementation of Lycopene in Carotid Atheroma |
| NCT01321268 | Not specified | TERMINATED | Safety and Efficacy of a Dietary Supplement in Females With Cellulite |
| NCT01665742 | Not specified | COMPLETED | Anti-inflammatory Dietary Intervention in Overweight and Obese Adolescents |
| NCT03492593 | Not specified | COMPLETED | Lycopene and Beta-carotene Metabolism in the Digestive Tract of Healthy Men |
| NCT03820245 | Not specified | COMPLETED | Effect of Short-term Annatto Carotenoids Supplementation on Oxidative Stress Status in Healthy Individuals |
| NCT05671562 | Not specified | COMPLETED | The Effect of Lycopene on Sperm Quality in Men Attending Fertility Clinic |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: coronary artery disorder, atherosclerosis